These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38788285)

  • 1. Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands.
    de Jager VD; Cajiao Garcia BN; Kuijpers CCHJ; de Bock GH; Maas WJ; Timens W; van Kempen LC; van der Wekken AJ; Schuuring E; Willems SM
    Eur J Cancer; 2024 Jul; 205():114125. PubMed ID: 38788285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice.
    Steeghs EMP; Groen HJM; Schuuring E; Aarts MJ; Damhuis RAM; Voorham QJM; ; Ligtenberg MJL; Grünberg K
    Lung Cancer; 2022 May; 167():87-97. PubMed ID: 35461050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
    Griesinger F; Eberhardt W; Nusch A; Reiser M; Zahn MO; Maintz C; Bernhardt C; Losem C; Stenzinger A; Heukamp LC; Büttner R; Marschner N; Jänicke M; Fleitz A; Spring L; Sahlmann J; Karatas A; Hipper A; Weichert W; Heilmann M; Sadjadian P; Gleiber W; Grah C; Waller CF; Reck M; Rittmeyer A; Christopoulos P; Sebastian M; Thomas M;
    Lung Cancer; 2021 Feb; 152():174-184. PubMed ID: 33358484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
    Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS
    Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting.
    Sireci AN; Krein PM; Hess LM; Khan T; Willey J; Ayars M; Deyoung K; Bhaskar S; Mumuney G; Coutinho A
    Clin Lung Cancer; 2023 Jul; 24(5):429-436. PubMed ID: 37080814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biopsy Procedures and Molecular Testing Utilization and Related Costs in Patients with Metastatic Lung Cancer.
    Shinde R; Cao X; Kothari S
    J Manag Care Spec Pharm; 2016 Oct; 22(10):1194-203. PubMed ID: 27668568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
    Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
    Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer.
    Kuijpers CCHJ; Hendriks LEL; Derks JL; Dingemans AC; van Lindert ASR; van den Heuvel MM; Damhuis RA; Willems SM
    Lung Cancer; 2018 Jul; 121():76-81. PubMed ID: 29858031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP).
    Salas C; Martín-López J; Martínez-Pozo A; Hernández-Iglesias T; Carcedo D; Ruiz de Alda L; García JF; Rojo F
    J Clin Pathol; 2022 Mar; 75(3):193-200. PubMed ID: 33722840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.
    Faber E; Grosu H; Sabir S; San Lucas FA; Barkoh BA; Bassett RL; Luthra R; Stewart J; Roy-Chowdhuri S
    J Clin Pathol; 2022 Sep; 75(9):612-619. PubMed ID: 33952592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor biomarker testing in non-small-cell lung cancer: A decade of change.
    VanderLaan PA; Rangachari D; Majid A; Parikh MS; Gangadharan SP; Kent MS; McDonald DC; Huberman MS; Kobayashi SS; Costa DB
    Lung Cancer; 2018 Feb; 116():90-95. PubMed ID: 29413057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated chromogenic multiplexed immunohistochemistry assay for diagnosis and predictive biomarker testing in non-small cell lung cancer.
    Ilie M; Beaulande M; Hamila M; Erb G; Hofman V; Hofman P
    Lung Cancer; 2018 Oct; 124():90-94. PubMed ID: 30268486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Biomarker and Programmed Death-Ligand 1 Expression Testing in Patients With Advanced Stage Non-small Cell Lung Cancer Across North Carolina Community Hospitals.
    Rivera MP; Charlot M; Durham DD; Throneburg A; Lane LM; Perera P; Samulski TD; Henderson LM
    Chest; 2021 Sep; 160(3):1121-1130. PubMed ID: 33887243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study.
    Garcia BNC; van Kempen LC; Kuijpers CCHJ; Schuuring E; Willems SM; van der Wekken AJ
    Lung Cancer; 2022 May; 167():1-7. PubMed ID: 35349855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data.
    John A; Yang B; Shah R
    Adv Ther; 2021 Mar; 38(3):1552-1566. PubMed ID: 33537872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database.
    Malapelle U; Passiglia F; Pepe F; Pisapia P; Lucia Reale M; Cortinovis D; Fraggetta F; Galetta D; Garbo E; Graziano P; Pagni F; Pasello G; Piovano P; Pilotto S; Tiseo M; Genova C; Righi L; Troncone G; Novello S
    Lung Cancer; 2024 May; 191():107787. PubMed ID: 38593479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variation in treatment and outcome in patients with non-small cell lung cancer by region, hospital type and volume in the Netherlands.
    Wouters MW; Siesling S; Jansen-Landheer ML; Elferink MA; Belderbos J; Coebergh JW; Schramel FM
    Eur J Surg Oncol; 2010 Sep; 36 Suppl 1():S83-92. PubMed ID: 20598845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knowledge and Practice Patterns Among Pulmonologists for Molecular Biomarker Testing in Advanced Non-small Cell Lung Cancer.
    Fox AH; Jett JR; Roy UB; Johnson BE; King JC; Martin N; Osarogiagbon RU; Rivera MP; Rosenthal LS; Smith RA; Silvestri GA
    Chest; 2021 Dec; 160(6):2293-2303. PubMed ID: 34181954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.